Previsión
El precio objetivo medio de los analistas es de 64,99 € (+48,11 %). La mediana es de 64,72 € (+47,49 %).
| Comprar |
13 |
| Mantener |
2 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Scholar Rock clarifies FDA requirements for ISEMBYLD, shares fall sharply
Scholar Rock confirmed that the FDA requires post‑marketing conditions for ISEMBYLD, including a study on safety in pregnancy and 15‑day adverse‑event reporting for bone fractures. Management had previously (and incorrectly) stated that no such conditions existed. The stock then fell 6.4% to $51.85 and declined 9.7% on the week. Scholar Rock said it will carry out the requested studies and reporting in line with FDA requirements; analysts subsequently adjusted ratings and price targets. » Más en de.investing.com
FDA grants approval for ISEMBYLD; Scholar Rock stock rises
The FDA approved ISEMBYLD (apitegromab-mstn) as the first muscle-specific treatment for spinal muscular atrophy in adults and children aged two and older who are already receiving an SMN2-directed therapy. The news pushed Scholar Rock’s stock up about 9% pre-market to $60.45 and converts the company into a commercial biopharma company. Several analysts sharply raised price targets and reiterated buy ratings; apitegromab is projected to generate billions in sales by 2035. Scholar Rock reports roughly $492 million in cash and has independent fill-and-finish and manufacturing capabilities for the product launch. » Más en de.investing.com
Scholar Rock receives FDA approval for Isembyld to treat SMA
The FDA has approved Isembyld (Apitegromab‑mstn) for the treatment of spinal muscular atrophy in patients aged two and older. The approval is based on the phase‑3 SAPPHIRE study, in which patients receiving Isembyld in addition to standard therapy showed a significant improvement on the Hammersmith scale after one year; 34.2% achieved an increase of at least three points versus 13.5% with placebo. The US commercial launch has begun, the stock climbed more than 14% to an all‑time high, and Scholar Rock is shifting from a clinical biotech company to a commercial drugmaker. » Más en deraktionaer.de
Scholar Rock prepares for FDA decision on apitegromab
Weeks before the PDUFA date on September 30, 2026, Scholar Rock highlights late Phase III data on apitegromab as well as secured commercial production and go‑to‑market infrastructure. After an earlier Complete Response Letter over manufacturing issues, the company moved commercial fill‑finish production to an alternative site and says it has already produced commercial vials there. Management emphasizes statistically significant Phase III results, high treatment adherence, and prepared sales, nursing and patient‑support structures for the US, with plans for Europe and Japan. » Más en de.investing.com
Scholar Rock nears approval for apitegromab
At the Cantor Fitzgerald Global Healthcare Conference, Scholar Rock said the FDA has identified compliance with manufacturing requirements as the only remaining approval hurdle and that the company has since established a contractually committed alternative fill-and-finish facility. The crucial PDUFA date is September 30, 2026; management is holding intensive talks with the FDA about labeling and safety data. Scholar Rock has roughly $500 million in cash, sees worldwide market potential in the billions, and expects initial but manageable reimbursement and market-access hurdles during the first three to five quarters after launch. » Más en de.investing.com
Datos financieros
En el último trimestre, SCHOLAR ROCK HLDG DL-,001 tuvo unos ingresos de 503,22 mil € y un beneficio neto de -94,68 M €
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 503,22 mil | - |
| Beneficio bruto | 496,16 mil | 101,15 % |
| Beneficio neto | -94,68 M | 8,69 % |
| EBITDA | -90,36 M | 5,55 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 5352,46 M € |
Número de acciones | 122 M |
Máximo/mínimo de 52 semanas | 56,30 € - 35,27 € |
| Dividendos | No |
Beta | 0,62 |
Ratio P/E | -14,95 |
Ratio PEG | 28,66 |
Ratio P/B | 37,77 |
Ratio P/S | 10.301,85 |
Perfil de la empresa
Scholar Rock Holding Corporation, una empresa biofarmacéutica, se centra en el descubrimiento y desarrollo de medicamentos para el tratamiento de enfermedades graves en las que la señalización por factores de crecimiento proteicos desempeña un papel fundamental. La compañía desarrolla Apitegromab, un inhibidor de la activación de la miostatina latente que ha completado los ensayos clínicos de fase 3 para el tratamiento de la atrofia muscular espinal; y SRK-181, que se encuentra en ensayos clínicos de fase 1 para el tratamiento de cánceres resistentes a las terapias con inhibidores de puntos de control, como las terapias con anticuerpos anti-PD-1 o anti-PD-L1. También desarrolla un portafolio de nuevos candidatos a medicamentos con potencial para transformar la vida de pacientes que padecen una serie de enfermedades graves, entre ellas trastornos neuromusculares, cáncer y fibrosis. La compañía tiene un acuerdo de colaboración con Gilead Sciences, Inc. para descubrir y desarrollar inhibidores específicos de la activación del factor de crecimiento transformante beta para el tratamiento de enfermedades fibróticas. Scholar Rock Holding Corporation fue fundada en 2012 y tiene su sede en Cambridge, Massachusetts.
| Nombre | SCHOLAR ROCK HLDG DL-,001 |
| CEO | David L. Hallal |
| Sede | Cambridge,
ma Estados Unidos |
| Sitio web | |
| Sector | Consumo básico |
| Industria | Productos alimenticios |
| Salida a bolsa | 25/05/2018 |
| Empleados | 289 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | SRRK |
Frankfurt | 2QK.F |
Düsseldorf | 2QK.DU |
München | 2QK.MU |